MedTrace Logo

A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fed)

NCT07083401 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-24

No results posted yet for this study

Summary

This was an open-label, randomized, fed, single-dose, 2-sequence, 2- period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.

Conditions

  • Diabete Mellitus

Interventions

DRUG

Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg

Orally administered once per day

DRUG

Dapagliflozin 10 mg

Orally administered once per day

DRUG

Pioglitazone 30 mg

Orally administered once per day

DRUG

Metformin HCl 1000 mg

Orally administered once per day

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-05
Primary Completion
2026-07-05
Completion
2026-07-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07083401 on ClinicalTrials.gov